All In Biotech

Guides

Orange Book vs Purple Book: patents, exclusivity and equivalence

Orange Book vs Purple Book explained: which drugs each FDA list covers, how patents, exclusivity and therapeutic equivalence codes work, and how to search both.

By the All In Biotech editorial team · Published November 18, 2026 · 6 min read

The Orange Book and the Purple Book are FDA's two reference lists for when competing versions of a drug can reach the market. The Orange Book covers drugs approved under the Federal Food, Drug, and Cosmetic Act, mostly small molecules, and lists their patents, exclusivity and therapeutic equivalence codes for generics. The Purple Book covers biologics licensed under the Public Health Service Act and shows biosimilars, interchangeable products and reference product exclusivity.

This site does not host data from either book. Use FDA's own search tools, linked below, for any decision that depends on them.

The two books side by side

Orange BookPurple Book
Full nameApproved Drug Products with Therapeutic Equivalence EvaluationsLists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations
Legal basisFederal Food, Drug, and Cosmetic Act (Hatch-Waxman, 1984)Public Health Service Act section 351 (Biologics Price Competition and Innovation Act, 2009)
ProductsNDA drugs and their generics (ANDAs)Licensed biologics (BLAs), biosimilars and interchangeables
Copies are calledGenericsBiosimilars or interchangeable biosimilars
Equivalence shown byTherapeutic equivalence codes (AB, BX and so on)Biosimilar or interchangeable status
Brand exclusivity for a new active ingredient5 years (new chemical entity)12 years (reference product)
PatentsListed by the brand company for each NDAListed after patent exchanges with biosimilar applicants
Where to searchOrange Book searchPurple Book search

The Orange Book

FDA's Orange Book dates to 1980, and the Hatch-Waxman Act of 1984 made it central to generic drug approval. It lists approved prescription and over-the-counter drug products, along with discontinued products, and for each NDA the patents and exclusivity periods that can delay generic approval.

Therapeutic equivalence codes

The TE code is the field pharmacists use most. FDA considers two products therapeutically equivalent when they are pharmaceutical equivalents (same active ingredient, dosage form, route and strength) and are expected to have the same clinical effect and safety profile.

Codes starting with A mean FDA considers the product therapeutically equivalent. Codes starting with B mean it does not, at least not yet.

  • AB: equivalent, with actual or potential bioequivalence problems resolved by adequate evidence. This is the "AB-rated generic" most state substitution laws rely on.
  • AB1, AB2 and so on: used when there are several reference drugs. A generic coded AB1 is equivalent to products coded AB1, not to those coded AB2.
  • AA, AN, AO, AP, AT: equivalent products in dosage forms with no known bioequivalence problems (AA), or specific forms such as aerosols (AN), injectable oils (AO), injectable aqueous solutions (AP) and topical products (AT).
  • B codes (BC, BD, BE, BN, BP, BR, BS, BT, BX): not considered equivalent. BX means the data are insufficient to decide.

The book's preface explains every code. Products with no TE code may simply have no approved equivalent.

Patents and exclusivity

NDA holders must list patents that claim the drug substance, the drug product (formulation or composition) or an approved method of use. A generic applicant must certify against each listed patent. A "Paragraph IV" certification says the patent is invalid or will not be infringed. If the brand company sues within 45 days, FDA generally cannot give final approval to the generic for 30 months, unless the case is resolved sooner.

Exclusivity is separate from patents. It is granted by FDA under the statute and blocks approval, or in some cases submission, of competing applications. The main periods:

  • New chemical entity: 5 years for a drug with an active moiety FDA has not approved before.
  • New clinical investigation: 3 years for changes, such as a new use, that required new clinical studies.
  • Orphan drug: 7 years for an approved use in a designated rare disease.
  • Pediatric: 6 months added to existing patents and exclusivity when the company completes studies FDA requested.
  • First generic: 180 days for the first generic applicant to file a Paragraph IV challenge.
  • Qualified infectious disease product: 5 years added to certain other exclusivities for qualifying antibacterial and antifungal drugs.

FDA explains the rules in its Orange Book preface and data files, which can be downloaded free.

The Purple Book

The Purple Book began as two lists in 2014 and became a searchable database in 2020. It lists biological products licensed under section 351 of the Public Health Service Act, both those regulated by CDER, such as monoclonal antibodies, and those regulated by CBER, such as vaccines and cellular and gene therapies.

Biosimilar and interchangeable

A biosimilar is highly similar to an already licensed reference product, with no clinically meaningful differences in safety, purity and potency. An interchangeable biosimilar has also met additional requirements, so a pharmacist may substitute it for the reference product without the prescriber's involvement, subject to state pharmacy law.

The Purple Book shows each product's status, its reference product and its licensure date. FDA's approach to the data needed for interchangeability has changed in recent years, so check FDA's biosimilars pages for current policy. The later post on biosimilars and interchangeable biologics covers this in more depth.

Exclusivity and patents

A reference biologic gets 12 years of exclusivity from first licensure, during which FDA cannot approve a biosimilar that relies on it. A biosimilar application cannot even be submitted until 4 years after the reference product's first licensure. Orphan exclusivity and pediatric exclusivity also apply to biologics. The first interchangeable biosimilar for a reference product can earn its own period of exclusivity against later interchangeables.

Patents work differently from the Orange Book. Biologic makers do not list patents up front. Instead the biosimilar applicant and the brand company exchange patent lists under a process in the statute, and since the Purple Book Continuity Act of 2020, FDA publishes the patent lists the brand company provides.

Which book is a product in?

The answer depends on the law the product was approved under, not on how it looks or works.

  • Small-molecule drugs and their generics: Orange Book.
  • Antibodies, fusion proteins, vaccines, blood products, cell and gene therapies: Purple Book.
  • Insulins, human growth hormone, hyaluronidase and some other proteins: these were once approved as NDAs. On March 23, 2020, under the Biologics Price Competition and Innovation Act, they were deemed to be BLAs and moved to the Purple Book. That is why insulin biosimilars, not insulin generics, now exist.
  • Peptides: depends on size and history. Semaglutide, for example, is approved under NDAs. You can see this on this site's catalog: Ozempic is an NDA, while Keytruda is a BLA.

In this site's Drugs@FDA catalog, as of November 2026, 5,412 of the 5,899 brand-name applications are NDAs and 487 are BLAs. Most CBER-licensed biologics are not in Drugs@FDA at all, so the Purple Book is the better list for them.

How to search each book

  1. Orange Book: open the search page and search by proprietary name, active ingredient, application number or patent number. Open the product to see TE codes, then the patent and exclusivity tabs with expiration dates.
  2. Purple Book: open the Purple Book search and search by product or proper name. The results show the licensure date, the reference product, biosimilar or interchangeable status and any exclusivity date.

What the books cannot tell you

  • When a generic or biosimilar will actually launch. Patent litigation, settlements and business decisions often set the date, and they are not in either book.
  • Whether a listed patent is valid. FDA lists patents but does not judge them.
  • Price or coverage. Neither book has pricing. For Medicare spending, see this site's Medicare spending tool.

Exclusivity and patent dates change as supplements are approved and litigation proceeds, so recheck the books before relying on a date. For the difference between NDAs, BLAs and ANDAs in more detail, read NDA vs BLA vs ANDA.

Frequently asked questions

What is the difference between the Orange Book and the Purple Book?
The Orange Book covers drugs approved under the Federal Food, Drug, and Cosmetic Act, mostly small molecules and their generics, while the Purple Book covers biologics licensed under the Public Health Service Act, including biosimilars.
What does an AB rating mean in the Orange Book?
An AB code means FDA considers the generic therapeutically equivalent to the reference drug, with any potential bioequivalence problem resolved by adequate evidence.
Are insulins in the Orange Book or the Purple Book?
Since March 2020, insulins and certain other proteins approved as drugs have been deemed biologics, so they are listed in the Purple Book.
How long is exclusivity for a new biologic?
A reference biologic gets 12 years of exclusivity from first licensure before FDA can approve a biosimilar, and no biosimilar application can be submitted until 4 years after licensure.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading